[Intravascular malignant lymphomatosis]

H Mertz1, V H Danchell

  • 1Aalborg Sygehus, patologisk institut.

Ugeskrift for Laeger
|January 7, 1998
PubMed

Insights

Intravascular malignant lymphomatosis (IML) is a rare lymphoma. Early diagnosis and chemotherapy offer potential for remission in this aggressive condition.

Area of Science:

  • Oncology
  • Hematology
  • Pathology

Background:

  • Intravascular malignant lymphomatosis (IML) is a rare extranodal non-Hodgkin lymphoma.
  • Characterized by malignant lymphoid cell proliferation within small blood vessel lumens.

Observation:

  • A case of IML presented with non-specific pulmonary symptoms, weight loss, and fever.
  • Cardiac, cerebral, and skin lesions developed subsequently.
  • The patient died within six months, with diagnosis confirmed at autopsy.

Findings:

  • IML diagnosis was established post-mortem.
  • The condition presented with a complex and evolving set of symptoms mimicking various organ ischemia.

Implications:

  • Standard chemotherapy for high-grade lymphomas may achieve remission and long-term survival.
  • IML should be considered in the differential diagnosis of unexplained ischemic symptoms affecting multiple organs.